Cory Kasimov
Stock Analyst at Evercore ISI Group
(4.31)
# 412
Out of 5,030 analysts
79
Total ratings
57.14%
Success rate
16.9%
Average return
Main Sectors:
Stocks Rated by Cory Kasimov
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CYTK Cytokinetics | Maintains: Outperform | $60 → $80 | $58.44 | +36.89% | 1 | Sep 3, 2025 | |
| VIR Vir Biotechnology | Initiates: Outperform | $12 | $5.78 | +107.61% | 1 | Sep 3, 2025 | |
| IMNM Immunome | Initiates: Outperform | $18 | $15.67 | +14.87% | 1 | Aug 22, 2025 | |
| SMMT Summit Therapeutics | Maintains: Outperform | $30 → $34 | $20.99 | +61.98% | 2 | Aug 12, 2025 | |
| XENE Xenon Pharmaceuticals | Initiates: Outperform | $55 | $41.63 | +32.12% | 1 | May 14, 2025 | |
| MRNA Moderna | Maintains: In-Line | $50 → $32 | $26.01 | +23.03% | 6 | May 2, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Outperform | $190 → $185 | $140.09 | +32.06% | 2 | Apr 24, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $45 → $50 | $54.92 | -8.96% | 3 | Dec 23, 2024 | |
| EWTX Edgewise Therapeutics | Maintains: Outperform | $45 → $50 | $15.06 | +232.12% | 2 | Dec 17, 2024 | |
| BNTX BioNTech SE | Upgrades: Outperform | $110 → $125 | $105.14 | +18.89% | 4 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $115 → $105 | $53.29 | +97.04% | 12 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $1,250 → $1,175 | $578.05 | +103.27% | 5 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $85 | $86.95 | -2.24% | 1 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $84 → $88 | $32.64 | +169.65% | 6 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $324 → $276 | $143.00 | +93.01% | 4 | Dec 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $35 | $5.03 | +595.83% | 1 | Mar 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $225 → $232 | $298.81 | -22.36% | 5 | Jul 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $87.57 | - | 5 | May 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $122.81 | - | 5 | May 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $21 | $30.26 | -30.60% | 4 | Feb 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $83 → $23 | $5.47 | +320.48% | 6 | Nov 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $310 → $250 | $9.83 | +2,443.23% | 1 | Feb 14, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $15 → $10 | $1.42 | +604.23% | 1 | Feb 14, 2018 |
Cytokinetics
Sep 3, 2025
Maintains: Outperform
Price Target: $60 → $80
Current: $58.44
Upside: +36.89%
Vir Biotechnology
Sep 3, 2025
Initiates: Outperform
Price Target: $12
Current: $5.78
Upside: +107.61%
Immunome
Aug 22, 2025
Initiates: Outperform
Price Target: $18
Current: $15.67
Upside: +14.87%
Summit Therapeutics
Aug 12, 2025
Maintains: Outperform
Price Target: $30 → $34
Current: $20.99
Upside: +61.98%
Xenon Pharmaceuticals
May 14, 2025
Initiates: Outperform
Price Target: $55
Current: $41.63
Upside: +32.12%
Moderna
May 2, 2025
Maintains: In-Line
Price Target: $50 → $32
Current: $26.01
Upside: +23.03%
Neurocrine Biosciences
Apr 24, 2025
Maintains: Outperform
Price Target: $190 → $185
Current: $140.09
Upside: +32.06%
BridgeBio Pharma
Dec 23, 2024
Maintains: Outperform
Price Target: $45 → $50
Current: $54.92
Upside: -8.96%
Edgewise Therapeutics
Dec 17, 2024
Maintains: Outperform
Price Target: $45 → $50
Current: $15.06
Upside: +232.12%
BioNTech SE
Nov 19, 2024
Upgrades: Outperform
Price Target: $110 → $125
Current: $105.14
Upside: +18.89%
Oct 30, 2024
Maintains: Outperform
Price Target: $115 → $105
Current: $53.29
Upside: +97.04%
Oct 24, 2024
Maintains: Outperform
Price Target: $1,250 → $1,175
Current: $578.05
Upside: +103.27%
May 14, 2024
Initiates: Outperform
Price Target: $85
Current: $86.95
Upside: -2.24%
Feb 27, 2024
Maintains: Overweight
Price Target: $84 → $88
Current: $32.64
Upside: +169.65%
Dec 21, 2021
Maintains: Neutral
Price Target: $324 → $276
Current: $143.00
Upside: +93.01%
Mar 1, 2021
Initiates: Neutral
Price Target: $35
Current: $5.03
Upside: +595.83%
Jul 29, 2020
Maintains: Neutral
Price Target: $225 → $232
Current: $298.81
Upside: -22.36%
May 6, 2020
Downgrades: Neutral
Price Target: n/a
Current: $87.57
Upside: -
May 1, 2020
Downgrades: Neutral
Price Target: n/a
Current: $122.81
Upside: -
Feb 14, 2020
Downgrades: Neutral
Price Target: $25 → $21
Current: $30.26
Upside: -30.60%
Nov 2, 2018
Maintains: Underweight
Price Target: $83 → $23
Current: $5.47
Upside: +320.48%
Feb 14, 2018
Maintains: Neutral
Price Target: $310 → $250
Current: $9.83
Upside: +2,443.23%
Feb 14, 2018
Maintains: Underweight
Price Target: $15 → $10
Current: $1.42
Upside: +604.23%